ASH 2023 | Oral combination of ASTX727 (decitabine/cedazuridine) plus Ven for older/unfit patients with AML

Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses data from a Phase II study of ASTX727 (decitabine/cedazuridine) plus venetoclax (Ven) in front-line and relapsed/refractory patients with acute myeloid leukemia (AML) who are older age (≥ 75 yrs) and/or unfit for intensive chemotherapy. The combination of hypomethylating agents (HMA) plus venetoclax is the standard of care for patients with AML; however, the requirement to be in hospital to receive this treatment can be challenging. This study included 52 patients and showed that in an older and very high-risk population of patients with AML, an entirely oral regimen of ASTX727 and venetoclax is effective, and the safety profile is tolerable. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.